Lund Melanoma Study Group
1 – 10 of 279
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Desmoplastic melanoma in Sweden in 2009–2022 : A population-based registry study demonstrating distinctive tumour characteristics, incidence and survival trends
- Contribution to journal › Article
-
Mark
Characteristics and overall survival in patients with T1 melanoma : A nationwide matched cohort study
- Contribution to journal › Article
-
Mark
Five-year survival after introduction of adjuvant treatment in stage III melanoma : A nationwide registry-based study
- Contribution to journal › Article
-
Mark
Treatment and outcome for 2,111 patients with vermilion lip squamous cell carcinoma : A nationwide, population-based study from the SweHNCR
- Contribution to journal › Article
-
Mark
SWE-NEO : Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial
- Contribution to journal › Letter
-
Mark
Authors’ reply regarding “Does tattoo exposure increase the risk of cutaneous melanoma : A population based case-control study”
(2026) In European Journal of Epidemiology
- Contribution to journal › Letter
-
Mark
Weight trajectories and obesity onset between 17 and 60 years of age, and cause-specific mortality: the Obesity and Disease Development Sweden (ODDS) pooled cohort study
- Contribution to journal › Article
-
Mark
Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III–IV melanoma : A retrospective cohort study
- Contribution to journal › Article
-
Mark
Impact of occult metastasis size on mortality in stage IIIA melanoma : a Swedish population-based registry study
- Contribution to journal › Debate/Note/Editorial
-
Mark
Neoplastic and non-neoplastic astrocyte states converge on mesenchymal and injury-response programs during glioblastoma recurrence
- Contribution to journal › Article
